In a meta-analysis of 40 trials (1,540 patients) of CAR T-cell therapy for relapsed/refractory B-cell ALL, pooled complete remission was 83.4%. 4-1BB constructs had higher MRD-negative remission than CD28 (94.0% vs 84.4%) and less neurotoxicity.
Meta-analysisn = 1,540
Navarro et al. CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis